



Stabilis



Colistin mesilate sodium



Noms commerciaux

Alfacolin	Argentine
Alficetin	Argentine
Colent	Chili
Colimicina	Espagne, Italie
Colimycin	Danemark, Norvège, Turquie
Colimycine	France, Luxembourg, Maroc, Pays bas, Tunisie
Colismet	Pérou
Colisti Ject	Egypte
Colistimetal sodic	Roumanie
Colistimetato de sodio	Chili, Espagne, Pérou
Colistimethate	Canada, Etats Unis d'Amérique, Grande Bretagne
Colistin	Autriche, Grèce, Nouvelle Zélande, Pologne
Colistina	Argentine, Portugal
Colistineb	Belgique
Colistyn	Argentine
Colixin	Portugal
Colomycin	Canada, Etats Unis d'Amérique, Grande Bretagne, Irlande, Malaisie
Coly-Mycin	Australie, Etats Unis d'Amérique
Cotrelan	Argentine
Dicupal	Chili
Elistin	Pérou
Kolisod	Turquie
Nolisin	Argentine
Promixin	Grande Bretagne, Irlande, Norvège
Toliscrin	Argentine



Stabilité des solutions

		200 mg/ml	25°C		7			2285
		200 mg/ml	4°C		7			2285
		75 mg/ml	-20°C		24			3360

		75 mg/ml	21°C		24				3360
		75 mg/ml	4°C		24				3360
PVC		4 mg/ml	4°C		48				2285
POF		1,6 mg/ml	2-8°C		7				4178
POF		1,6 mg/ml	20-24°C		1				4178
PI		0,8 & 2,4 mg/ml	2-8°C		7				4178
PI		0,8 & 2,4 mg/ml	20-24°C		1				4178
SI		0,8 mg/ml	4°C		3				2783



Facteur influençant la stabilité

				2285
				2285



Compatibilités

	Colistin mesilate sodium : 4.5 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528	
	Colistin mesilate sodium : 1.5 mg/ml Ceftazidime : 5 mg/ml		3997	
	Colistin mesilate sodium : 4.5 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828	
	Colistin mesilate sodium : 1.5 mg/ml Cimetidine hydrochloride : 3 mg/ml		1201	
	Colistin mesilate sodium Cromoglycate sodium		2550	
		Colistin mesilate sodium : 4.5 mg/ml Eravacycline : 0,6 mg/ml		4434
	Colistin mesilate sodium : 1.5 mg/ml Ertapenem : 5 mg/ml		3997	
		Colistin mesilate sodium Erythromycin lactobionate		3674
	Colistin mesilate sodium : 1.5 mg/ml Fosfomycin : 20 mg/ml		3997	
	Colistin mesilate sodium : 4.5 mg/ml Fosfomycin : 30 mg/ml		4055	
	Colistin mesilate sodium : 1.5 mg/ml Imipenem - cilastatin sodium : 5/5 mg/ml		3997	
		Colistin mesilate sodium : 4.5 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Colistin mesilate sodium : 1.5 mg/ml Linezolid : 2 mg/ml		3997	

	Colistin mesilate sodium : 1.5 mg/ml Meropenem : 10 mg/ml		3997	
	Colistin mesilate sodium : 75 mg/ml Meropenem : 50 mg/ml		4319	
	Colistin mesilate sodium : 1.5 mg/ml Piperacillin sodium / tazobactam : 40/0.5 mg/ml		3997	
	Colistin mesilate sodium : 4.5 mg/ml Plazomicin sulfate : 24 mg/ml		4145	
	Colistin mesilate sodium : 4,5 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801	
	Colistin mesilate sodium : 4.5 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827	
	Colistin mesilate sodium : 4,5 mg/ml Telavancin hydrochloride : 7,5 mg/ml		3254	
		Colistin mesilate sodium : 4,5 mg/ml Telavancin hydrochloride : 7,5 mg/ml		3254
		Colistin mesilate sodium : 4,5 mg/ml Telavancin hydrochloride : 7,5 mg/ml	RL	3254
	Colistin mesilate sodium : 1.5 mg/ml Vancomycin hydrochloride : 10 mg/ml		3997	
	Colistin mesilate sodium : 0,8 mg/ml		4438	



Voie d'administration





Bibliographie


	Type	Source
1201	Revue	Yuhás EM, Lofton FT, Rosenberg HA, Mayron D, Baldinus JG. Cimetidine hydrochloride compatibility III: Room temperature stability in drug admixtures. Am J Hosp Pharm 1981 ; 38: 1919-1922.
2285	Revue	Wallace SJ, Li J, Rayner CR, Coulthard K, Nation RL. Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients. Antimicrob Agents Chemother 2008 ; 52, 9: 3047-3051.
2550	Revue	Roberts GW, Rossi S.O.P. Compatibility of nebulizer solutions Aust J Hosp Pharm 1993 ; 23: 35-37.
2783	Revue	Abdulla A.,van Leeuwen R.W.F, de Vries Schultink A.H.M.,Koch B.C.P. Stability of colistimethate sodium in a disposable elastomeric infusion device. Int J Pharm 2015 ; 486; 1-2: 367-369.
3254	Revue	Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L. Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3360	Revue	Healan A. M, Gray W, Fuchs E.J, Griffiss J.M, Salata R.A, Blumer J. Stability of Colistimethate Sodium in Aqueous Solution. Antimicrob Agents Chemother 2012 ; 56:6432-6433.

3674	Laboratoire	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3997	Revue	Katip W. Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055	Revue	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Revue	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4178	Revue	Post T.E, Kamerling I, van Rossen R, Burggraaf J, Stevens J, Dijkmans A, Heijerman H, Touw D, van Velzen A, Wilms E. Colistin methanesulfonate infusion solutions are stable over time and suitable for home administration. EJHP 2017 ; 25, e2
4319	Revue	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4434	Revue	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4438	Revue	Stawny M, Gostyńska A, Nadolna M, Jelińska A. Safe Practice of Y-Site Drug Administration: The Case of Colistin and Parenteral Nutrition Pharmaceutics 2020 ; 12: 292
4528	Revue	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4801	Revue	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Stabilis



Colistin mesilate sodium



Stabilité des préparations

?		80 mg Colistin CF	NaCl 0.9% >> 3 mL	2-8°C	?	48	<input checked="" type="checkbox"/>	3334
?		80 mg Colistin CF	NaCl 5,85 % >> 3 mL	2-8°C	?	48	<input checked="" type="checkbox"/>	3334



Stabilité en mélange

PP		25°C		Tobramycin sulfate : Flacon injectable Bramitob® (Asche Chiesi) 300mg/5mL	24	<input checked="" type="checkbox"/>	3440
PP		25°C		Tobramycin sulfate : Flacon injectable Tobi® (Novartis) 300mg/5mL	24	<input checked="" type="checkbox"/>	3440
PP		25°C		Tobramycin sulfate : Flacon injectable Bramitob® (Asche Chiesi) 300mg/5mL	24	<input checked="" type="checkbox"/>	3440



Compatibilités

	Colistin mesilate sodium Ipratropium bromide	2550



Bibliographie

	Type	Source
2550	Revue	Roberts GW, Rossi S.O.P. Compatibility of nebulizer solutions Aust J Hosp Pharm 1993 ; 23: 35-37.
3334	Revue	Krämer I, Walz-Jung H, Stanko C, Kamin W. Physicochemical compatibility of nebuliser solution admixtures containing colistimethate and hypertonic saline or colistimethate, fluticasone-17-propionate, ipratropium bromide and salbutamol sulfate. EJHP 2013 ;20:36-41
3440	Revue	Wollstadt A, Krämer I, Kamin W. Physicochemical compatibility of nebulizable drug admixtures containing colistimethate and tobramycin. Pharmazie 2013 ; 68: 744-748.



Dictionnaire

 Antibiotique	 Injectable
 Noms commerciaux	 Stabilité des solutions
 Contenant	 Molécule
 Concentration	 Température
 Conservation	 Durée de stabilité
 Biosimilaire	 Données conflictuelles
 Bibliographie	 Verre
 Eau pour préparation injectable	 A l'abri de la lumière
 Jour	 Heure
 Non précisée	 Polyvinyl chlorure
 NaCl 0,9% ou glucose 5%	 Polyoléfine
 Chlorure de sodium 0,9%	 Avec ou sans lumière
 Elastomère en polyisoprène	 Elastomère en silicone
 Facteur influençant la stabilité	 Augmentation
 Provoque	 Dégradation
 Diminution	 Diminution de la stabilité
 Compatibilités	 Molécule
 Solvant	 Compatible
 Glucose 5%	 Incompatible
 Turbidité immédiate	 Incompatibilité non précisée
RL Ringer lactate	 Nutrition parentérale (mélange ternaire)
 Voie d'administration	 Intraveineuse
 Perfusion intraveineuse	 Perfusion continue
 Intramusculaire	 Bibliographie
 Aérosol	 Stabilité des préparations
 Origine	 Excipient
 Non précisé	 Flacon injectable
 Stabilité en mélange	 Polypropylène
 Lumière	 Dictionnaire